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Abstract
We and other investigators have previously shown that
membrane-type 1 matrix metalloproteinase (MT1-MMP)
is overexpressed in invasive prostate cancer cells. How-
ever, the mechanism for this expression is not known.
Here, we show that MT1-MMP is minimally expressed in
nonmalignant primary prostate cells, moderately ex-
pressed in DU-145 cells, and highly expressed in in-
vasive PC-3 and PC-3N cells. Using human MT1-MMP
promoter reporter plasmids and mobility shift assays,
we show that Sp1 regulates MT1-MMP expression in
DU-145, PC-3, and PC-3N cells and in PC3-N cells using
chromatin immunoprecipitation analysis and silencing
RNA. Investigation of signaling pathway showed that
DU-145 cells express constitutively phosphorylated
extracellular stress–regulated kinase (ERK), whereas
PC-3 and PC-3N cells express constitutively phos-
phorylated AKT/PKB and c-Jun NH2 terminal kinase
(JNK). We show that MT1-MMP and Sp1 levels are
decreased in PC-3 and PC-3N cells when phosphati-
dylinositol-3 kinase and JNK are inhibited, and that
MT1-MMP levels are decreased in DU-145 cells when
MEK is inhibited. Transient transfection of PC-3 and
PC-3N cells with a dominant-negative JNK or p85,
and of DU-145 cells with a dominant negative ERK, re-
duces MT1-MMP promoter activity. These results in-
dicate differential signaling control of Sp1-mediated
transcriptional regulation of MT1-MMP in prostate can-
cer cell lines.
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Introduction
Prostate adenocarcinoma is the most commonly diagnosed
noncutaneous cancer and second leading cause of cancer-
related deaths in American men [1]. Death due to prostate
cancer is attributed to metastatic disease in which primary
tumors evade the prostate capsule and eventually metas-
tasize. This presents a large problem considering that
current diagnostic procedures do not readily determine
whether an individual with indolent disease will develop
aggressive metastatic disease. To reduce mortality due to
prostate cancer, it is imperative to develop an in-depth under-
standing of molecular events that occur during prostate cancer
progression and metastasis to identify key features and mo-
lecular alterations suitable for use as diagnostic markers or
therapeutic targets.
Matrix metalloproteinases are a family of zinc-binding pro-
teases that have been shown to contribute to prostate cancer
metastasis through their ability to degrade extracellular matrix
proteins [2,3]. Membrane type matrix metalloproteinases con-
sist of MT1, MT2, MT3, MT4, MT5, and MT6 MMP, and are
unique from other MMP family members in that they harbor a
transmembrane domain [4]. Membrane-type 1 matrix metallo-
proteinase (MT1-MMP) is an MT-MMP family member involved
in pericellular proteolysis associated with cell migration [5].
MT1-MMP is widely expressed in human tissues under nor-
mal and pathological conditions and is increased in numerous
types of tumors. In prostate cancer tissues, MT1-MMP ex-
pression is enhanced [6–8], and the enzyme has a prominent
role in increasing prostate cell migration through cleavage of
basement membrane proteins laminin-511 [9] and laminin-332
[8,10]. Although MT1-MMP expression is increased in pros-
tate cancer tumor tissues, evidence of elevated expression
in prostate tumor cell lines is variable. We and others have
previously shown that MT1-MMP becomes highly expressed in
invasive prostate cell lines compared to normal prostate cells
grown in culture [8,11,12]. However, other investigators have
reported that MT1-MMP mRNA expression is not increased in
prostate tumor cell lines [13]. In this study, we provide evidence
that MT1-MMP expression is indeed constitutively elevated in
prostate tumor cell lines and identify mechanisms of this
increased expression.
The regulation of MT1-MMP is complex and occurs through
both transcriptional and posttranscriptional mechanisms [5].
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MT1-MMP transcriptional control is unique compared to other
MMP family members due to differences in its promoter
sequence. Unlike most MMP family members, MT1-MMP
lacks the typical TATA box and contains a GC-rich sequence
immediately upstream of four transcriptional start sites [14].
Lohi et al. [14] identified this GC-rich region as the putative
binding sequence for the specificity protein-1 (Sp1) transcrip-
tion factor. Constitutive MT1-MMP regulation through Sp1
binding to the human promoter of MT1-MMP has been
identified in the context of HT-1080 fibrosarcoma cells [14]
and with the murine MT1-MMP promoter in microvascular
endothelial and rat glomerular mesangial cells [15,16].
Sp1 is a zinc finger transcription factor of the Sp/Kruppel–
like factor family, which regulates constitutive levels of genes
involved in various physiological processes, including apop-
tosis, angiogenesis, and cell cycle regulation in both normal
and malignant tissues [17]. Sp1 is overexpressed in gastric
[18] and pancreatic cancers [19], and has a prominent role in
regulating genes involved in angiogenesis such as vascular
endothelial growth factor (VEGF) [20,21]. Interestingly, Sp1
has also been shown to regulate genes involved in pros-
tate cancer metastasis, including urokinase plasminogen
activator (uPA), prostate-specific antigen (PSA), and the a6
integrin subunit [22–24]. Sp1 activity is modified through
posttranslational modifications, including phosphorylation
[25]. Phosphorylation of Sp1 in serine and threonine resi-
dues located throughout the entire length of the protein
results in functional alterations that increase either DNA
binding or transactivation activities. Although the precise
Sp1 residues phosphorylated have been mapped for sev-
eral kinases, including DNA-PK, cyclin D1, and extracellu-
lar signal–regulated kinase (ERK) 1/2 (as reviewed in Chu
and Ferro [25]), numerous studies indicate that additional
kinases also regulate Sp1. Kinase pathways, including the
c-Jun NH2-terminal kinase (JNK) pathway and the phospha-
tidylinositol-3 kinase (PI3K) pathway, through AKT, have
been shown to increase Sp1 phosphorylation and the trans-
activation of target genes [20–22].
Notably, the AKT, JNK, and ERK pathways have also
been implicated in regulating MT1-MMP independently of
Sp1 in various cell systems. AKT signaling has been shown
to increase MT1-MMP expression through various stimuli in
human pancreatic cancer and in a Lewis lung carcinoma
subline [26,27]. Additionally, JNK and PI3K signaling in-
creased MT1-MMP in endothelial cells, and JNK was spe-
cifically implicated in increasing MT1-MMP expression in
endothelial cells [28]. Activated ERK signaling was also
shown to regulate MT1-MMP in HT1080 [29] and in cervical
cancer cells [30], and downregulation of constitutive ERK
was shown to inhibit MT1-MMP in various types of tumor cell
lines [31]. However, constitutive regulation of MT1-MMP
through these pathways has not been investigated in pros-
tate cancer cell lines.
In this study, we document for the first time that MT1-
MMP expression in prostate cancer is dependent on Sp1.
We also show that levels of MT1-MMP vary in different pros-
tate cancer cell lines and that these levels directly correlate
with and are dependent on the differential expression of
constitutive kinase signaling pathways in each cell line.
Interestingly, cells expressing the highest levels of MT1-
MMP express constitutive AKT and JNK, whereas cells
expressing moderate levels of MT1-MMP express constitu-
tive ERK. We show for the first time that inhibition of these
pathways in prostate cancer decreases MT1-MMP expres-
sion. These results indicate that MT1-MMP regulation in
prostate cancer cell lines is a complex process dependent
on Sp1 regulation and on the constitutive activity of signaling
pathways involved with tumor progression.
Materials and Methods
Reagents and Cell Culture
Human prostate cancer DU-145 and PC-3 cells (American
Type Tissue Collection, Manassas, VA) and PC-3N cells
(variant of PC-3 cells described previously) [32] were main-
tained in Iscove’s modified Dulbecco’s medium (IMDM;
Invitrogen Life Technologies, Carlsbad, CA) supplemented
with 100 mg/ml penicillin, 100 mg/ml streptomycin (Invitrogen
Life Technologies), and 10% fetal bovine serum (FBS; Gemini
Bioproducts, Woodland CA). Human prostate primary epithe-
lial cells (PrEC) were obtained from Clonetics (Cambrex, East
Rutherford, NJ) and maintained in Clonetics-recommended
PreGM medium. All cells were maintained at 37jC in a
humidified 5% CO2 incubator. The Western blot analysis
antibody against MT1-MMP (AB815 polyclonal) was from
Chemicon (Millipore, Billerica, MA), and Sp1 polyclonal was
from Santa Cruz Biotechnologies (Santa Cruz, CA). Anti-
bodies against phosphorylated and total ERK, AKT, and
JNK were from Cell Signaling Technologies (Danvers, MA),
and a-tubulin monoclonal antibody was from Calbiochem
(San Diego, CA). Antibodies used for mobility shift assays
and chromatin immunoprecipitation (ChIP) include Sp1 poly-
clonal and rabbit IgG from Santa Cruz Biotechnologies, and
Sp3 polyclonal fromGeneka (Montreal, Canada). The specific
inhibitor for PI3K (LY294002) was obtained from LC Labora-
tories (Woburn, MA). Specific inhibitors for JNK (SP600125)
and MEK (PD98059) were obtained from Calbiochem.
Plasmid Constructs
MT1-MMP luciferase reporter constructs (MT-LUC) used
to study MT1-MMP expression have been described pre-
viously and were a kind gift from Dr. Jorma Keski-Oja
(Department of Virology and Pathology, Haartman Institute
of Helsinki, Helsinki, Finland). The parent vector for the
MT-LUC expression vector pGL3 basic was obtained from
Promega (Fitchburg, WI). Dominant-negative ERK and JNK
constructs were kind gifts from Dr. Z. Dong (Hormel Insti-
tute, University of Minnesota, Austin, MN), and dominant-
negative p85 and SR a control vectors were a kind gift
from Dr. Q. Chen (Department of Pharmacology, College
of Medicine, University of Arizona, Tuczon, AZ) and were
originally described by Dr. M. Kasuga (Kobe University
School of Medicine, Kobe, Japan). The control vectors for
the dominant-negative ERK and JNK vectors were pcEP4
and pCMV5, respectively (Invitrogen Life Technologies).
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Transient Transfection and Luciferase Analysis
PC-3N, PC-3, and DU-145 cells were grown to log phase
by splitting 24 hours before trypsinization, counted using
a Coulter Counter (Beckman Coulter, Fullerton, CA), and
plated in varying densities in 0.5 ml of IMDM supplemented
with 10% FBS in 24-well plates. On the following day, the
cells were transfected with FUGENE 6 Reagent (Roche
Applied Science, Indianapolis, IN), according to the manu-
facturer’s instructions, using equimolar concentrations of all
MT-LUC constructs (300 ng/well of a 7.2-kb construct and
approximately 100 ng/well of 0.1-kb, 0.4-kb, 1.2-kb, and
pGL3 basic) and 1 ml of FUGENE 6 per 0.5 ml of medium
in each well of the 24-well plates. Renilla luciferase vector
pRL-SV-40 (Promega) was used as transfection control at
1 ng/well. For studies using dominant-negative vectors, equi-
molar concentrations of dominant-negative JNK (DN-JNK)
and a dominant-negative vector of PI3K p85 subunit (DN-
p85), and a 1:2 molar ratio of MT-LUC to the dominant-
negative ERK (DN-ERK) and pcEP4 vectors were added to
FUGENE 6. Cells transfected with the DN-p85 and DN-ERK
vectors were cotransfected with 10 ng/well pRK-TKRenilla
control vector, and cells transfected with the DN-JNK vec-
tors were cotransfected with 1 ng/well pRL-SV-40Renilla
(Promega). All transfection experiments were performed
overnight in serum-free medium, which was replaced with
10% FBS medium for an additional 24 hours. Cells were
then lysed and analyzed using the Dual Luciferase Reporter
Assay System (Promega), according to the manufacturer’s
instructions. For each experiment, firefly luciferase activity
was normalized to the activity of Renilla luciferase as an in-
ternal control. The results were expressed as fold induction,
determined by normalizing each firefly luciferase value to the
Renilla luciferase internal control and by dividing these
normalized values with the mean normalized value of the
corresponding reporter construct transfected with empty ex-
pression vectors. Values represent three independent ex-
periments performed in triplicate, and data are expressed
as mean ± SD. Statistical analysis was performed using
Student’s t test.
Preparation of Nuclear Extracts
Prostate cancer cells, grown to 80% confluency in 100-mm
dishes, were lysed in 1 ml of ice-cold buffer A (10 mMHEPES
pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM fresh DTT, and
0.1% Nonidet P-40) and transferred to 1.5-ml Eppendorf
tubes. Samples were rocked on an inversion rocker for 1 hour
at 4jC before centrifugation at 14,000 rpm for 15 minutes
at 4jC. Supernatant was removed, and nuclear pellet was
resuspended in 10 ml of buffer C (20 mM HEPES pH 7.9,
25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA,
0.5 mM DTT, and 0.5 mM phenylmethanesulphonylfluoride
[PMSF]). Samples were incubated at 4jC on an inversion
rocker and centrifuged at 14,000 rpm for 15 minutes. Su-
pernatants were diluted 1:5 with buffer D (20 mM HEPES
pH 7.9, 20% glycerol, 1.5 mM MgCl2, 100 mM KCl, 0.2 mM
EDTA, 0.5 mM DTT, and 0.5 mM PMSF) before protein
quantitation using Bio-Rad Protein Assay (Bio-Rad Laborato-
ries, Hercules, CA).
Electrophoretic Mobility Shift Assay (EMSA)
The oligonucleotide corresponding to the sequence de-
rived from the human MT1-MMP promoter containing a puta-
tive Sp1 site (5V- GGCACTGGGGCGGGGACGGAGG-3V and
3V-CGTGACCCCGCCCCTGCCT-5V) was overhung labeled
with 32P. Five micrograms of nuclear extracts isolated from
prostate cancer cell lines was incubated on ice with 5
binding buffer (50 mM HEPES pH 7.9, 250 mM KCl, 0.5 mM
EDTA, 12.5 mM DTT, 50% glycerol, and 0.25% Nonidet
P-40), and 50 or 100 wild-type nonlabeled competitor or
mutant nonlabeled competitor (5V-GGCACTGGTTCGGGG-
GACGGAGG-3V and 3V-CGTGACCTTGCCCCTGCCT-5V)
was incubated for 1 hour on ice. Samples containing nuclear
extract and 5 binding buffer for supershift analysis were
incubated with anti–Sp1 polyclonal antibody (Santa Cruz
Biotechnologies) or anti–Sp3 polyclonal antibody (Geneka)
for 1 hour on ice. Following a 1-hour incubation on ice,
50,000 cpm of labeled wild-type probe (1 ml) was added to
each reaction and incubated for 20 minutes at 25jC. Samples
were resolved on a nondenaturing 4% polyacrylamide gel in
0.25 Tris–borate–EDTA, dried, and visualized by phosphor-
imaging (Molecular Dynamics, Sunnyvale, CA).
ChIP Assay
ChIP assay was performed using the EZCHIP Kit (Up-
state Biotechnology, Lake Placid, NY) with slight modifica-
tions. PC-3N cells (2  107) were cross-linked with 1%
formaldehyde in 10 ml of serum-free medium for 10 minutes
at room temperature, followed by the addition of 1 ml of 10
glycine to quench unreacted formaldehyde. Cells were
washed twice with ice-cold phosphate-buffered saline con-
taining protease inhibitor cocktail II (Millipore) and then
scraped and centrifuged at 700g at 4jC for 5 minutes.
Pelleted cells were lysed with 1 ml of sodium dodecyl sulfate
(SDS) lysis buffer (1% SDS, 10 mM EDTA, and 50 mM Tris
pH 8.1) supplemented with protease inhibitor cocktail and
incubated on ice for 10 minutes. After sonication to produce
genomic DNA with lengths of 0.2 to 1 kb (optimized at 10
15-second pulses), samples were centrifuged at 13,000g for
10 minutes to remove insoluble materials. Lysates were
diluted in ChIP dilution buffer (0.01% SDS, 1.1% Triton
X-100, 2 mM EDTA, 20 mM Tris–HCl pH 8.1, and 500 mM
NaCl) and protease inhibitor cocktail. Dilutions of chromatin
preparations were reserved as input and stored at 80jC.
Chromatin solution was precleared with 100 ml of salmon
sperm DNA/protein A agarose for 2 hours at 4jC with
rotation. Anti–Sp1 polyclonal (Santa Cruz Biotechnologies)
antibody was added to the precleared supernatant and
incubated overnight at 4jC with rotation. On the following
day, 60 ml of salmon sperm DNA/protein A agarose slurry
was added to the chromatin solution for 1 hour with rotation
at 4jC. Negative controls included a sample incubated
without antibody and one incubated with rabbit IgG (Santa
Cruz Biotechnologies) to determine whether interactions
were not due to nonspecific IgG interactions. Bead com-
plexes were washed first with low-salt immune complex
wash buffer, followed by high-salt immune complex wash
buffer and a final LiCl immune complex wash buffer for
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5 minutes each on a rotating platform followed by brief
centrifugation. Two final washes in 1 TE buffer were
performed for 5 minutes each. After the final wash, DNA
was extracted by incubating the beads twice for 15 minutes
with 250 ml of freshly made elution buffer (1% SDS and
50 mM NaHCO3). Samples were then uncrosslinked in a
65jC water bath overnight, and DNA was purified using
Qiagen Nucleotide Removal Kit (Qiagen, Valencia, CA).
Polymerase chain reaction (PCR) primers used to amplify
the MT1-MMP promoter region flanking the Sp1-binding
site were as follows: CTGCGATCTAAGTAAGCTTGGC (for-
ward) and GTTTGCTCTTCTCCTCTTTTCCG (reverse).
Sp1 Small Interfering RNA (siRNA)
The siGENOME silencing RNA smart pool targeting Sp1
and siCON nontargeting smart pool were purchased from
DharmaconResearch (Lafayette, CO). Transfection was per-
formed as suggested by Dharmacon Research, with slight
modifications. Briefly, PC-3N cells were plated at 1  106
cells per T75 flask (BD/Falcon, Mississauga, Ontario, Can-
ada) and then transfected on the following day with Sp1
siRNA or siCON oligonucleotide siRNA pools using Dharma-
fect reagent 2 (Dharmacon Research) for 24 hours in a
serum-containing medium. On the following day, the me-
dium was replaced with a fresh-serum–containing medium,
and cells were harvested for examining the expression of
Sp1 protein and MT1-MMP protein and mRNA levels. Each
siRNA experiment was performed at least three times, and
Western blot analysis indicates one representative experi-
ment. Real-time reverse transcription (RT) PCR data in-
clude three separate experiments, and data are expressed
as mean ± SD. Statistical analysis was performed using
Student’s t test.
Total Cellular Protein Extraction and Western Blot Analysis
Cells were lysed in 50 mM Tris–Cl (pH 7.4), 150 mM
NaCl, 1 mM EDTA, 1% sodium deoxycholate, 1% Triton
X-100, 1 mg/ml aprotinin, 1 mg/ml leupeptin, 3 mM b-glycerol
phosphate, 1 mM Na3VO4, 10 mM NaF, and 10 mM sodium
pyrophosphate. Cells were scraped and centrifuged at
14,000 rpm for 10 minutes at 4jC. Bio-Rad Dc reagent
(Bio-Rad Laboratories) was used to determine protein con-
centration. For Western blot analysis, 30 mg of protein was
resolved on a 10% SDS polyacrylamide gel. The protein was
then transferred to a polyvinylidene difluoride membrane
(Millipore) for 1.5 hours using the Invitrogen Small Cell
Transblot Apparatus (Invitrogen Life Technologies). Fol-
lowing transfer, the membranes were blocked in 5% nonfat
milk in Tris-buffered saline Tween-20 (TBST) at room tem-
perature for 1 hour. The primary antibodies for MT1-MMP
(AB815; Chemicon) and Sp1 (Santa Cruz Biotechnologies)
were used at 1:2000 and incubated overnight at 4jC in 5%
nonfat dry milk/TBST. Membranes were incubated with
appropriate horseradish peroxidase secondary antibody in
5% milk/TBST for 1 hour at room temperature. The primary
antibody for a-tubulin (Calbiochem), which was used as a
loading control, was used at 1:5000 and incubated at room
temperature for 2 hours. Goat anti–mouse horseradish
peroxidase secondary (Transduction Laboratories, Green-
land, NH) was used at 1:2000 for the a-tubulin antibody, and
anti–rabbit horseradish peroxidase (Cell Signaling, Beverly
MA) was used at 1:2000 dilution for all other antibodies
mentioned previously. Membranes were washed thrice for
10 minutes each in TBST between antibody incubations
and were detected using ECL Western blot analysis detec-
tion reagents (Amersham Biosciences, Buckinghamshire,
England, UK).
Real-Time PCR
Total RNA was isolated using the TRIZOL method (Invi-
trogen Life Technologies), and 1 mg of isolated RNA was
reverse-transcribed using the High Capacity cDNA Kit (Ap-
plied Biosystems, Foster City, CA). TaqMan Gene Expres-
sion Assay probes were purchased for MT1-MMP (Applied
Biosystems), and real-time PCR was performed using the
TaqMan Universal PCR Master Mix and the ABI PRISM
7700 Sequence Detection System (Applied Biosystems).
PCR conditions were as follows: 50jC for 20 minutes,
95jC for 10 minutes, followed by 40 cycles of 95jC for
15 seconds and 60jC for 1 minute. Relative CT method
was used to calculate mRNA levels of MT1-MMP normalized
to GAPDH in each sample, as described by User Bulletin 2,
ABI PRISM 7700 Sequence Detection System. Results in-
clude three separate experiments, and data are expressed
as mean ± SD. Statistical analysis was performed using
Student’s t test.
Results
MT1-MMP Is Expressed in Prostate Tumor Cell Lines
and Is Regulated By Sp1
Previous studies in our laboratory have shown that MT1-
MMP expression is increased in highly invasive prostate
tumor cell lines [8]. However, there has also been a report
that MT1-MMP is not expressed in the prostate tumor cell
lines used in this study [13]. To demonstrate that MT1-MMP
expression is indeed increased in human prostate tumor cell
lines, the normal human prostate cell strain PrEC and the
human prostate tumor cell lines DU-145, PC-3, and PC-3N
were grown to 80% confluency, and total RNA and protein
were collected and analyzed by quantitative real-time RT-
PCR or Western blot analysis, respectively. The results in
Figure 1, A and B, indicate increased MT1-MMP mRNA and
protein in DU-145, PC-3, and PC-3N cells compared to
PrEC. The results indicate that PC-3N cells express the
highest levels of both mRNA and protein. Previous studies
have identified a GC-rich Sp1-binding region in the proximal
promoter of MT1-MMP, and Sp1 binding to this putative site
is a prominent mechanism of the transcriptional regulation of
MT1-MMP expression in multiple cell lines [8,14–16]. To
determine whether Sp1 transcriptionally regulates MT1-
MMP in human prostate cells, DU-145, PC-3, and PC-3N
cells were transiently transfected with a series of previously
described firefly luciferase reporter plasmids containing 94,
385, 1246 bp, or approximately 7.2 kb of the 5V-flanking
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region and the entire 5V untranslated sequence up to nucleo-
tide +200 relative to the 3V most major transcription start site
[14]. The results in Figure 1C (shown as DU-145, PC-3, and
PC-3N from left to right, respectively) indicate that the 94-bp
5V-flanking region (0.1 WT), which does not contain the
putative Sp1 site (located92 bp from the first transcriptional
start site), shows slightly enhanced promoter activity com-
pared to pGL3 basic. However, transfection with 385-bp
(0.4 WT), 1246-bp (1.2 WT), and 7.2-kb (7.2 WT) constructs,
which each contain the Sp1 site, significantly increased
promoter activity for DU-145, PC-3, and PC-3N cell lines
compared to pGL3 basic. The reduction in MT1-MMP pro-
moter activity in the 1246-bp (1.2 WT) construct compared to
the 385-bp construct has also been previously reported to
occur in HT-1080 cells [14] and is suggestive of a negative
regulatory element. To determine the role of Sp1 in regulating
MT1-MMP, a series of constructs with the Sp1 site deleted
(Sp1-MUT) was transfected into each cell line. Activity for
each construct was significantly reduced when comparing
wild-type vectors with mutant vectors of the same size.
These results indicate that the putative Sp1 site in the
proximal promoter of MT1-MMP plays a significant role in
regulating the transcription of the enzyme in the three human
prostate cell lines.
Sp1 Binds to the MT1-MMP Promoter
To determine the ability of endogenous nuclear Sp1 to
bind to the putative Sp1 site in the proximal promoter of MT1-
MMP, nuclear extracts from PC-3N, PC-3, and DU-145 cells
were used in an EMSA, as shown in Figure 2A. One distinct
DNA–protein complex (lanes 2, 7, and 12) was formed from
nuclear extracts of all three cell lines, as well as frommultiple
smaller bands due to nonspecific binding. The addition of
excess unlabeled wild-type Sp1 oligonucleotides efficiently
competed for DNA–protein complex formation in each cell
line (lanes 3, 8, and 13), whereas mutant oligonucleotides
did not inhibit complex formation (lanes 4, 9, and 14). To
define Sp1 as the nuclear protein associating with putative
Sp1 sequence, Sp1 antibody was added to binding reac-
tions, which resulted in clearing of a specific band and a
Figure 1. MT1-MMP is expressed in prostate cell lines and its promoter activity is dependent on Sp1. (A) Quantitative real-time RT-PCR analysis of MT1-MMP
mRNA in PrEC p2 (passage 2), DU-145, PC-3, and PC-3N cells. Values represent the average of MT1-MMP normalized to GAPDH and fold induction over the
PrEC for three independent experiments. Columns, means; bars, SD. P < .05 for all cell lines compared to PrEC. (B) Western blot analysis of MT1-MMP expression
was performed on three human tumor cell lines (DU-145, PC-3, and PC-3N) and one normal human prostate cell line (PrEC) at two separate passages (p2 and p3).
Western blot analysis results are representative of at least three experiments, which are depicted graphically as fold induction over PrEC passage 2, and a-tubulin
is shown as a loading control. Columns, mean; bars, SD. P < .05 for all cell lines compared to PrEC. (C) Three prostate tumor cells were transiently transfected
with MT1-MMP promoter constructs of variable length (94, 385, 1246 bp, and f 7.2 kb upstream of the closest transcription start site, including the entire 5 V
untranslated region of MT1-MMP linked to firefly luciferase in pGL3 basic; 0.1, 0.4, 1.2, and 7.2, respectively). Both wild-type (WT) and Sp1 mutants (MUT) were
transfected into DU-145, PC-3, and PC-3N cells (shown from left to right, respectively). Values represent luciferase activity normalized to the activity of pSV-
40 Renilla control and are represented as fold over control (pGL3 basic) for each cell line in three independent experiments. Columns, mean; bars, SD. *P < .05 for
each wild-type construct versus the Sp1 mutant construct for each cell line. Statistical analyses were performed using Student’s t test.
410 AKT, JNK, and ERK Regulate MT1-MMP through Sp1 in Prostate Cancer Cells Sroka et al.
Neoplasia . Vol. 9, No. 5, 2007
supershifted DNA–protein band (lanes 5, 10, and 15). It has
previously been shown that the Sp1 family member Sp3
binds to the putative Sp1 sequence with similar affinity, but
has negative regulatory functions on its target genes [17].
An anti-Sp3 antibody was added to the binding reactions to
ensure that endogenous Sp3 was not formulating a shifted
DNA–protein complex (lanes 6, 11, and 16). To ensure the
specificity of supershift antibodies, a nontargeting antibody
(anti–a-tubulin) was added to the binding reactions and did
not result in a shift of the Sp1 DNA–protein complex (data
not shown). These results indicate that endogenous Sp1 in
DU-145, PC-3, and PC-3N cells binds to the putative Sp1
sequence in the proximal promoter of MT1-MMP in a cell-
free system. To define Sp1 as the nuclear protein binding to
the putative Sp1 site in the MT1-MMP promoter in live cells,
PC-3N cells were used to perform a ChIP assay because
they express the highest levels of MT1-MMP. Results from
the ChIP assay in Figure 2B indicate that Sp1 does indeed
bind to the MT1-MMP promoter in live cells, as shown by the
249-bp amplicon produced when an anti-Sp1 antibody was
added to the immunoprecipitation reaction (lane 2). Lane 1
depicts a positive control and is a PCR amplicon from
chromatin isolated before immunoprecipitation. Important
negative controls to ensure the specificity of the anti-Sp1
antibody include rabbit IgG (lane 3), no antibody (lane 4), and
no DNA control for PCR (lane 5). These results indicate that
Sp1 binds to the MT1-MMP promoter in PC-3N cells.
Silencing RNA Targeting Sp1 Decreases
MT1-MMP Expression
To evaluate the Sp1 regulation of MT1-MMP expression
in vivo, we used silencing of RNA targeting Sp1 in PC-3N
cells. Transfection of PC-3N cells with siRNA targeting
Sp1 for 48 and 72 hours (data not shown) depleted the
protein from the cells, as shown by Western blot analysis
(Figure 3A). Depletion of Sp1 from PC-3N cells at 48 hours
significantly reduced MT1-MMP mRNA levels detected by
quantitative real-time RT-PCR (Figure 3B). Additionally,
MT1-MMP protein levels were reduced at 48 hours (data
not shown) and depleted at 72 hours, as assessed by
Western blot analysis (Figure 3C). These data indicate that
Sp1 is required for MT1-MMP expression in PC-3N cells.
Figure 2. Sp1 binds to the MT1-MMP promoter in human prostate tumor cell lines. (A) EMSA analysis with oligonucleotides corresponding to the Sp1 sequence in
the proximal MT1-MMP promoter and nuclear extracts from PC-3N cells (lanes 2–6), PC-3 cells (lanes 7–11), and DU-145 cells (lanes 12–16). Lane 1: Free
probe only. Lanes 2, 7, and 12: Prostate cell line nuclear lysates (NL) and probe only. Lanes 3, 8, and 13: 50 wild-type (WT) competitor. Lanes 4, 9, and 14: 50
mutant competitor (MUT). Lanes 5, 10, and 15: Supershift with anti-Sp1 antibody. Lanes 6, 11, and 16: No supershift with anti-Sp3 antibody. (B) PC-3N cells were
processed by ChIP assay followed by PCR to produce a 249-bp amplicon. Lane 1: Input DNA amplified from chromatin before immunoprecipitation. Lane 2:
Amplicon produced from chromatin isolated using an anti-Sp1 antibody during immunoprecipitation: Lanes 3 to 5: Negative controls indicating no amplicon
produced when using control IgG antibody (lane 3), no antibody (lane 4), and absence of DNA as a PCR control (lane 5). All results shown are representative of at
least three independent experiments.
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AKT, JNK, and ERK Are Differentially Phosphorylated
in Three Prostate Cell Lines
The AKT and JNK pathways influence Sp1 phosphoryla-
tion [21,22], and ERK directly phosphorylates Sp1 to increase
its transcriptional activity [22,33–36] and these pathways be-
come overexpressed in prostate cancer [37–41]. Western
blot analysis was performed to investigate possible consti-
tutive signaling mechanisms involved in the differential ex-
pression of MT1-MMP in DU-145, PC-3, and PC-3N human
prostate tumor cell lines grown in a medium supplemented
with 10% FBS. Western blot analysis in Figure 4 indicates
blots probed for phosphorylated AKT, ERK, and JNK, with
total protein used as a loading control. The results show
that PC-3 and PC-3N cells express constitutively phosphory-
lated AKT on serine 473 and phosphorylated JNK, whereas
DU-145 cells do not express constitutive AKT or JNK. The
constitutively active AKT observed in PC-3 and PC-3N cells
coincides with previous reports on prostate cancer cell PTEN
status and our unpublished data on PC-3N cells [42]. Addi-
tionally, the results in Figure 4 also show that DU-145 cells
express constitutively phosphorylated ERK, whereas PC-3
and PC-3N cells do not. These data indicate differential
constitutive signaling in DU-145, PC-3, and PC-3N prostate
cell lines.
MT1-MMP Expression Is Regulated through the PI3K
and JNK Pathways in PC-3N and PC-3 Cells and
through the ERK Pathway in DU-145 Cells
To investigate the possible role of constitutively active
signaling pathways in the regulation of MT1-MMP, PC-3N
and PC-3 cells were treated with the PI3K small molecule
inhibitor (LY294002) and the JNK small molecule inhibitor
(SP600125) at 30 mM for 48 hours. Western blot analysis
for AKT phosphorylation in cells treated with LY294002 and
for JNK phosphorylation in cells treated with SP600125 in-
dicated a decrease in the phosphorylation of both kinases
(data not shown). Western blot analysis was performed
for MT1-MMP and Sp1 expression (Figure 5A), and the
results indicate that treatment of PC-3N and PC-3 cells (data
not shown) resulted in a decrease in both Sp1 and MT1-
MMP protein levels. Using quantitative real-time RT-PCR, it
was also determined that treatment with LY294002 and
SP600125 decreased MT1-MMP mRNA levels at 48 hours
(Figure 5B) in PC-3N and PC-3 cells (data not shown). To
Figure 3. Silencing RNA targeting Sp1 decreases MT1-MMP expression. PC-3N cells were transfected with either siCON (nonspecific targeting siRNA pool) or an
Sp1 siRNA pool (Dharmacon Research) at 25 nM. (A) Western blot analysis of Sp1 in PC-3N cells transfected for 48 hours, with a-tubulin shown as a loading
control. (B) Quantitative real-time RT-PCR of MT1-MMP mRNA expression following PC-3N transfection for 48 hours. Values represent the average of MT1-MMP
normalized to GAPDH for three independent experiments. Columns, mean; bars, SD. *P < .05. Statistical analyses were performed using Student’s t test. (C)
Western blot analysis of MT1-MMP in PC-3N cells transfected for 72 hours, with a-tubulin shown as a loading control. All Western blot analysis results are
representative of at least three independent experiments.
Figure 4. Constitutive AKT, JNK, and ERK signaling pathways in prostate
cancer cell lines. DU-145, PC-3, and PC-3N cells were grown in 10% FBS
and IMDM until approximately 80% confluent. Cells were lysed and analyzed
by Western blot analysis using the indicated antibodies against phosphory-
lated AKT, ERK, and JNK. To verify equal loading, the blots were stripped
once and reprobed with antibodies against total protein. Results are
representative of at least three independent experiments.
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ensure specificity in inhibiting the PI3K and JNK pathways
in PC-3N and PC-3 cells, transient cotransfection with
dominant-negative p85 or JNK with the 385-bp MT1-MMP
luciferase promoter construct was performed. The results in
Figure 5C indicate a significant decrease in MT1-MMP pro-
moter expression in cells transfected with either dominant-
negative p85 or dominant-negative JNK1 compared to empty
parent vector. To investigate the possible role of constitu-
tive ERK activity in regulating MT1-MMP in DU-145 cells,
the cells were treated with the MEK small molecule inhibi-
tor (PD98059) to inhibit ERK phosphorylation (data not
shown) at 10 and 20 mM for 48 hours. MT1-MMP expression
was determined by Western blot analysis (Figure 5D), and
the results indicate decreased MT1-MMP levels with in-
creased drug concentration at 48 hours. Western blot analy-
sis of Sp1 indicated no change in total protein levels on
treatment with PD98059 (data not shown). Additionally,
transient cotransfection of dominant-negative ERK with the
385-bp MT1-MMP luciferase reporter vector significantly
reduced MT1-MMP promoter activity compared to the empty
parent vector control. These results indicate that inhibition
of constitutive AKT and JNK in PC-3N and PC-3 cells de-
creases MT1-MMP and Sp1 expression, and inhibition of
the constitutive ERK pathway in DU-145 cells decreases
MT1-MMP expression.
Discussion
This study was designed to characterize endogenous mecha-
nisms regulating constitutive levels of MT1-MMP in prostate
cancer cell lines. Previously, we have reported that MT1-
MMP is highly expressed in the invasive prostate PC-3N cell
line (a variant of PC-3 cells) and is slightly increased in the
less invasive PC-3 and DU-145 cells [8]. Tran et al. have
characterized the invasive characteristics of these cell lines
and have established that PC-3N cells displayed an invasive
phenotype in intraperitoneal injections into SCID mice, where-
as DU-145 cells did not exhibit invasive characteristics. In
contrast to our previous results depicting increased MT1-
MMP expression in invasive prostate cell lines, it has been
reported that there is no increased MT1-MMP expression in
DU-145 or PC-3 cells [13]. In this study, we demonstrate that
Figure 5. Involvement of PI3K, JNK, and ERK in regulating MT1-MMP expression in prostate cancer cells. (A) Western blot analysis for MT1-MMP and Sp1
expression. PC-3N cells were plated and allowed to adhere overnight. On the following day, the cells were treated with a specific inhibitor for PI3K (LY294002) or
JNK (SP600125) at 30 M in 10% serum medium for 48 hours. Results are representative of at least three independent experiments, and a-tubulin is shown as a
loading control. (B) PC-3N cells treated with the protocol in (A) were analyzed by quantitative real-time RT-PCR for MT1-MMP mRNA expression. Values represent
the average of MT1-MMP normalized to GAPDH for three independent experiments. Columns, mean; bars, SD. *P < .05 for treatment with inhibitors versus DMSO
control. (C) DN-p85 or DN-JNK was cotransfected with the 385-bp MT1-MMP promoter luciferase construct using equimolar ratios. Luciferase activity was
normalized to the activity of pSV-40 Renilla control for samples transfected with the DN-JNK vector, and samples transfected with DN-p85 were normalized to the
activity of pRL-TK Renilla. Values represent results for three independent experiments and are represented as fold over empty vector control in three independent
experiments *P < .05 for each dominant-negative cotransfection compared to empty vector control. (D) Western blot analysis for MT1-MMP expression. DU-145
cells were plated and allowed to adhere overnight. On the following day, cells were treated with the MEK inhibitor (PD98059) at 10 and 20 M in 10% serum
medium for 48 hours. Results are representative of at least three independent experiments, and a-tubulin is shown as a loading control. (E) DN-ERK was
cotransfected with the 385-bp MT1-MMP promoter luciferase construct at a ratio of 1:2. Values represent firefly luciferase activity for three independent
experiments normalized to the activity of pSV-40 Renilla control and are represented as fold under cells transfected with the pcEP4 empty vector. *P < .05 for
dominant-negative construct compared to empty vector. All statistical analyses were performed using Student’s t test.
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MT1-MMP is indeed significantly overexpressed in PC-3N
cells, marginally overexpressed in PC-3 and DU-145 (PC-3
slightly higher than DU-145 cells), and absent in the PrEC
(primary prostate cell strain).
Our group has published that fibroblast growth factor-1
induced MT1-MMP in LnCaP cells through transcriptional
activation by STAT-3 [43]. In this study, we focused on the
constitutive Sp1 regulation of MT1-MMP based on evidence
from reports implicating the transcription factor in regulating
MT1-MMP in other cell systems. Lohi et al. have previously
characterized the MT1-MMP promoter and implicated Sp1
as the prominent transcriptional regulator of MT1-MMP in
human fibroscarcoma HT-1080 cells. Additional groups also
identified the constitutive Sp1 regulation of the murine MT1-
MMP promoter in various cell lines [14–16]. Furthermore,
Sp1 is a zinc finger transcription factor that regulates genes
involved with angiogenesis and metastasis, including VEGF,
uPA, PSA, and the a6 integrin subunit [20–24]. Therefore,
we sought to determine whether Sp1 played a role in
regulating MT1-MMP in prostate tumor cells [3]. Here, we
show for the first time that MT1-MMP expression in three
prostate cell lines is dependent on Sp1 transcriptional con-
trol. Our results indicate that Sp1 regulates the MT1-MMP
promoter in cultured cells, as shown by transient transfection
experiments. Additionally, nuclear Sp1 from all three prostate
tumor cell lines bound to the MT1-MMP promoter in a cell-
free system and in PC-3N cells through mobility shift assays
and ChIP, respectively. Depletion of Sp1 from PC-3N cells
by silencing RNA inhibited MT1-MMP expression, indicating
the important role of the Sp1 transcriptional activity of the
enzyme in PC-3N cells.
Interestingly, levels of Sp1 (both total cell lysate or nuclear
lysate) do not vary significantly between the prostate cell
lines (data not shown), suggesting that posttranslational
regulation of Sp1 alters its transcriptional activity in the
MT1-MMP promoter in the three prostate cell lines. In-
creased Sp1 activity due to altered phosphorylation has been
associated with direct phosphorylation by ERK and has been
correlated with the PI3K and JNK pathways [20–22,35]. The
PI3K pathway has been implicated in prostate cancer pro-
gression through loss of the PTEN tumor suppressor [37–
39], and additional investigators have established a role for
increased JNK in advanced prostate cancer [22,41]. How-
ever, reports of ERK activation in prostate cancer have been
somewhat controversial. Gioeli et al. [44] concluded that
ERK is increased in advanced prostate cancer, whereas
Malik et al. [37] concluded that ERK expression is increased
in prostatic intraepithelial neoplasia but is decreased in
advanced disease. Our results indicate that the invasive
PC-3N and PC-3 prostate cancer cell lines express consti-
tutive AKTand JNK, whereas DU-145 cells are less invasive
and express constitutive ERK. It has been shown that JNK
activity has a negative effect on ERK activity [45], which
suggests that, in DU-145 cells, ERK activity prevails due to
inactivity of JNK. It is important to note that PC-3 cells have
levels of MT1-MMP and an invasive phenotype that fall in
between DU-145 and PC-3N cells, but they also express
constitutive AKT and JNK. This suggests that invasive cells
Figure 6. Proposed signaling regulation of MT1-MMP and Sp1 in prostate cancer cell lines. (A) Invasive prostate cancer PC-3N and PC-3 cells express high levels
of MT1-MMP, which is dependent on Sp1 transcriptional regulation. Inhibition of constitutively active PI3K or JNK pathways, both pharmacologically and
genetically, decreases MT1-MMP and Sp1 expression. The exact mechanisms of these pathways in regulating Sp1 are not known. (B) DU-145 prostate cancer
cells express lower levels of MT1-MMP compared to PC-3 and PC-3N cells, which is also dependent on Sp1 transcriptional regulation. Inhibition of constitutively
active ERK, both pharmacologically and genetically, reduces MT1-MMP expression. This model indicates that varying levels of MT1-MMP in prostate cancer cell
lines are regulated through the differential activation of signaling pathways and Sp1. The model suggests that AKT and JNK pathways mediate a more invasive
phenotype than the ERK pathway through increased modulation of MT1-MMP expression.
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are more dependent on PTEN mutations, and we hypothe-
size that there is a switch in signaling mechanisms from
active ERK to active AKTand JNK as cells become invasive.
PC-3N cells have significantly higher levels of MT1-MMP
and are highly invasive compared to PC-3 cells, and we
speculate that PC-3N may have unique regulatory factors
that influence or interact with Sp1 to enhance MT1-MMP
expression, in addition to constitutive AKT and JNK.
Our results and model in Figure 6 indicate that pharmaco-
logical inhibition of PI3K and JNK decreases MT1-MMP and
Sp1 levels in PC-3 and PC-3N cells. Although several studies
have correlated the AKT-mediated and JNK-mediated phos-
phorylation of Sp1 with increased transcriptional activity,
those studies have not definitively identified direct sites phos-
phorylated on Sp1 by these kinases. Evidence from this study
demonstrates a novel finding in that constitutively active
PI3K and JNK modulate Sp1 protein levels in two prostate
cancer cell lines. This finding indicates alternative mecha-
nisms of Sp1 regulation through the PI3K and JNK pathways
than what has been previously reported. Based on our re-
sults, we speculate that the PI3K and JNK pathways could
alter the transcription of the Sp1 gene through posttransla-
tional modification of Sp1, as it has recently been shown that
Sp1 regulates its own promoter [46]. We hypothesize that
inhibition of PI3K and JNK may alter Sp1 activity in binding
to its own promoter, therefore decreasing total Sp1 levels in
the cell. In addition to transcriptional regulation, we also
speculate that PI3K and JNK may be modulating Sp1 protein
levels through mechanisms of protein degradation. It has
been recently reported by Abdelrahim and Safe that COX-2
inhibitors in colon cancer cell lines decreased total Sp1 levels
but did not affect Sp1 mRNA levels. The authors concluded
that COX-2 inhibition enhanced proteosomal degradation of
Sp1 [47]. This report did not delineate the exact mechanisms
mediating Sp1 degradation, but it established proteosomal
degradation of Sp1 as a possible regulatory mechanism for
Sp1 expression.
Treatment of DU-145 cells with the MEK inhibitor PD98059
resulted in a decrease in MT1-MMP levels but did not result
in a decrease in Sp1 protein (data not shown). This suggests
that ERK regulation of Sp1 may not influence its transcrip-
tional activities for its own promoter or protein degradation
but does influence the transcriptional regulation of MT1-MMP.
In contrast to the lack of evidence of direct phosphorylation
mediated by AKTand JNK, previous studies have determined
the exact sites on Sp1 phosphorylated by ERK [33–35].
Additionally, these studies determined that ERK phosphory-
lation of Sp1 increases its transactivation activities. To in-
vestigate the role of ERK in directly phosphorylating Sp1 in
DU-145 cells, we performed transient transfections using a
previously described dominant-negative Sp1 [35] with mu-
tated ERK phosphorylation residues and the wild-type MT1-
MMP promoter in DU-145 cells. The results indicated that
a mutant Sp1 harboring mutated threonine residues directly
phosphorylated by ERK did not reduce the transcription of
the MT1-MMP promoter in these cells (data not shown).
Additionally, Western blot analysis of DU-145 cells treated
with the MEK inhibitor PD98059 to inhibit ERK activity did
not alter Sp1 phosphorylation (data not shown). Considering
this evidence, we speculate that inhibiting ERK activity, as
shown in Figure 5, D and E, in DU-145 cells decreases
Sp1-mediated MT1-MMP transcription in an indirect manner.
Results from this study indicate the prominent role of Sp1 in
regulating the transcription of MT1-MMP in DU-145 cells (as
shown in Figure 1B). We hypothesize that constitutive ERK
in these cells may regulate a downstream kinase or cofactor
involved with Sp1-mediated transcription.
In addition to the pharmacological treatment of the pros-
tate cells, we performed transient transfections to ensure
specificity in the inhibition of constitutive signaling pathways.
Transient transfection of PC-3 and PC-3N cells with either
dominant-negative JNK or p85 significantly decreased MT1-
MMP promoter activity. Furthermore, transient transfection
of DU-145 cells with dominant-negative ERK significantly
decreased MT1-MMP promoter activity. Notably, PC-3N and
PC-3 cells cotransfected with dominant-negative ERK, the
MT1-MMP promoter and DU-145 cells cotransfected with
dominant-negative p85 or JNK, and the MT1-MMP promoter
did not reduce MT1-MMP promoter activity in these cells
(data not shown). These experiments indicate that in PC-3
and PC-3N cells, PI3K and JNK play a role in regulating MT1-
MMP, and in DU-145 cells, the ERK pathway plays a role in
regulating MT1-MMP.
We speculate that multiple regulatory mechanisms medi-
ated by these pathways could be occurring in PC-3 and PC-
3N cells, as modeled in Figure 6. First, the pathways could
converge on a downstream regulator, and inhibition of either
pathway could negatively affect this unidentified regulator,
therefore decreasing Sp1 activity. Second, each pathway
may be required to phosphorylate Sp1 directly to achieve
transcriptional control of MT1-MMP, and the absence of one
pathway completely abrogates Sp1 activity. Third, there is a
possibility of direct crosstalk between the PI3K and JNK
signaling pathways, as shown by Logan et al. [48] in a study
that indicated PI3K regulation of JNK activity. This hypothe-
sis implies that JNK could be the dominant direct regulator of
Sp1 in PC-3 and PC-3N cells, but its activity could be de-
pendent on the constitutive signaling of PI3K. This hypothe-
sis is also supported by a study indicating that, in PC-3 cells,
JNK activity was constitutive and regulated Sp1-mediated
transcriptional control of uPA [22].
In conclusion, we have identified several novel findings.
We show for the first time that MT1-MMP expression in PC-
3N, PC-3, and DU-145 prostate cancer cell lines is depen-
dent on Sp1 transcriptional regulation. We also show that
constitutive signaling pathways in PC-3 and PC-3N cells,
namely, the PI3K and JNK pathways, play significant roles in
regulating MT1-MMP and Sp1 levels. Additionally, we show
that constitutive ERK in DU-145 cells plays a significant role
in regulating MT1-MMP levels, although the levels are lower
than those in PC-3 and PC-3N cells. This study exempli-
fies the heterogeneity in prostate cancer cell line signaling
mechanisms and the differential effects these pathways
have on the transcriptional control of MT1-MMP. Evidence
presented here suggests that constitutive PI3K and JNK ac-
tivities in prostate cancer cells influence invasive phenotype
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through increased transcription of MT1-MMP. This study also
indicates that ERK plays a minor role in this process in a cell
line that does not express PI3K and JNK pathways. This
study enhances our understanding of complex mechanisms
involved with MT1-MMP regulation and proposes that iden-
tifying trends in the aberrant expression of signaling cas-
cades involved in prostate cancer progression may aid in
determining future biomarkers or therapeutic targets.
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